These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19765296)

  • 61. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
    Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K
    Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
    Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Role of tyrosine kinase inhibitors in lung cancer.
    Ansari J; Palmer DH; Rea DW; Hussain SA
    Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs.
    Umekawa K; Kimura T; Kudoh S; Suzumura T; Oka T; Nagata M; Mitsuoka S; Matsuura K; Nakai T; Yoshimura N; Kira Y; Hirata K
    BMC Res Notes; 2013 Apr; 6():139. PubMed ID: 23566546
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer.
    Wong MK; Lo AI; Lam B; Lam WK; Ip MS; Ho JC
    Cancer Chemother Pharmacol; 2010 May; 65(6):1023-8. PubMed ID: 19680652
    [TBL] [Abstract][Full Text] [Related]  

  • 67. microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation.
    Shen Y; Tang D; Yao R; Wang M; Wang Y; Yao Y; Li X; Zhang H
    Med Oncol; 2013 Dec; 30(4):750. PubMed ID: 24198203
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives.
    Kim TY; Han SW; Bang YJ
    Expert Rev Mol Diagn; 2007 Nov; 7(6):821-36. PubMed ID: 18020911
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Personalized medicine and inhibition of EGFR signaling in lung cancer.
    Gazdar AF
    N Engl J Med; 2009 Sep; 361(10):1018-20. PubMed ID: 19692681
    [No Abstract]   [Full Text] [Related]  

  • 70. Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression.
    Bidkhori G; Moeini A; Masoudi-Nejad A
    PLoS One; 2012; 7(10):e48004. PubMed ID: 23133538
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.
    Phelps MA; Stinchcombe TE; Blachly JS; Zhao W; Schaaf LJ; Starrett SL; Wei L; Poi M; Wang D; Papp A; Aimiuwu J; Gao Y; Li J; Otterson GA; Hicks WJ; Socinski MA; Villalona-Calero MA
    Clin Pharmacol Ther; 2014 Aug; 96(2):182-91. PubMed ID: 24781527
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.
    Tsien CI; Nyati MK; Ahsan A; Ramanand SG; Chepeha DB; Worden FP; Helman JI; D'Silva N; Bradford CR; Wolf GT; Lawrence TS; Eisbruch A
    Head Neck; 2013 Sep; 35(9):1323-30. PubMed ID: 22907806
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Resistant mechanism and treatment strategy of tyrosine kinase inhibitors].
    Qiao J; Chen W
    Zhongguo Fei Ai Za Zhi; 2011 Oct; 14(10):806-10. PubMed ID: 22008111
    [No Abstract]   [Full Text] [Related]  

  • 74. [A case report of patient with advanced non-small cell lung cancer by five times EGFR-TKIs therapy].
    Guo W; Gao H; Liu X
    Zhongguo Fei Ai Za Zhi; 2013 Jun; 16(6):330-2. PubMed ID: 23769350
    [No Abstract]   [Full Text] [Related]  

  • 75. Metabolic profiling identifies lung tumor responsiveness to erlotinib.
    Fan TW; Lane AN; Higashi RM; Bousamra M; Kloecker G; Miller DM
    Exp Mol Pathol; 2009 Aug; 87(1):83-6. PubMed ID: 19409891
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Erlotinib in advanced well-differentiated thymic carcinoma with overexpression of EGFR: a case report.
    Pedersini R; Vattemi E; Lusso MR; Mazzoleni G; Ebner H; Graiff C
    Tumori; 2008; 94(6):849-52. PubMed ID: 19267104
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ileal perforation induced by acute radiation injury under gefitinib treatment.
    Muraoka T; Tsukuda K; Toyooka S; Kagawa S; Naomoto Y; Takemoto M; Katsui K; Kanazawa S; Maki Y; Masuda H; Harada M; Asano H; Naito M; Miyoshi S
    Int J Clin Oncol; 2011 Dec; 16(6):774-7. PubMed ID: 21706125
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-α mediated inflammatory diseases.
    Brooks MB
    Oncologist; 2013; 18(1):e3-5. PubMed ID: 23355622
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Differential Gene Expression in Erlotinib-Treated Fibroblasts.
    Wickersham KE; Hodges TK; Edelman MJ; Song Y; Nan M; Dorsey SG
    Nurs Res; 2019; 68(2):110-126. PubMed ID: 30540703
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors.
    Provencio M; García-Campelo R; Isla D; de Castro J
    Clin Transl Oncol; 2009 Jul; 11(7):428-36. PubMed ID: 19574200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.